- Home
- ARDX vs BXMX Comparison
ARDX vs BXMX Comparison
Compare ARDX & BXMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- BXMX
- Stock Information
- Founded
- ARDX 2007
- BXMX 2004
- Country
- ARDX United States
- BXMX United States
- Employees
- ARDX N/A
- BXMX N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- BXMX Investment Managers
- Sector
- ARDX Health Care
- BXMX Finance
- Exchange
- ARDX Nasdaq
- BXMX Nasdaq
- Market Cap
- ARDX 1.3B
- BXMX 1.5B
- IPO Year
- ARDX 2014
- BXMX N/A
- Fundamental
- Price
- ARDX $4.97
- BXMX $12.70
- Analyst Decision
- ARDX Strong Buy
- BXMX
- Analyst Count
- ARDX 8
- BXMX 0
- Target Price
- ARDX $10.19
- BXMX N/A
- AVG Volume (30 Days)
- ARDX 5.3M
- BXMX 205.6K
- Earning Date
- ARDX 05-01-2025
- BXMX 01-01-0001
- Dividend Yield
- ARDX N/A
- BXMX 7.24%
- EPS Growth
- ARDX N/A
- BXMX N/A
- EPS
- ARDX N/A
- BXMX N/A
- Revenue
- ARDX $333,615,000.00
- BXMX N/A
- Revenue This Year
- ARDX $15.74
- BXMX N/A
- Revenue Next Year
- ARDX $34.56
- BXMX N/A
- P/E Ratio
- ARDX N/A
- BXMX N/A
- Revenue Growth
- ARDX 168.06
- BXMX N/A
- 52 Week Low
- ARDX $4.02
- BXMX $11.75
- 52 Week High
- ARDX $9.33
- BXMX $13.75
- Technical
- Relative Strength Index (RSI)
- ARDX 51.65
- BXMX 49.80
- Support Level
- ARDX $4.54
- BXMX $12.00
- Resistance Level
- ARDX $5.07
- BXMX $12.75
- Average True Range (ATR)
- ARDX 0.30
- BXMX 0.43
- MACD
- ARDX 0.06
- BXMX 0.05
- Stochastic Oscillator
- ARDX 82.74
- BXMX 94.16
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.